ADHD is a neurodevelopmental condition that affects both children and adults. It is characterised by symptoms such as ...

Granules Pharmaceuticals, a wholly-owned subsidiary of Granules India, has received tentative approval from the US Food and ...

WASHINGTON — The Food and Drug Administration said on Monday it is revising the labeling of all extended-release stimulants used to treat attention-deficit hyperactivity disorder to include warnings ...

Granules India Ltd on Thursday said its arm Granules Pharmaceuticals, Inc has received tentative approval from the US health ...

The FDA now requires updated labeling for all extended-release stimulant medications used to treat attention deficit hyperactivity disorder, warning of increased risk of weight loss and other side ...

Kenvue, the American company that makes Tylenol, says the U.S. Food and Drug Administration should not make proposed changes to the product’s safety label to reflect research about a possible ...

KANSAS CITY, Kan., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Cingulate Inc. (CING) (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform ...

"We've had to work on her study skills, but there's no way she'd go back to taking the drugs." While doctors don't endorse patients with /topics/Attention_Deficit_Disorders" ...

NeuroSigma completes a $1M investment in high-volume manufacturing for its drug-free ADHD device. Learn how the Monarch eTNS ...

Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio") today announced that China's National Medical Products Administration (NMPA) has approved the New Drug Application for Serdexmethylphenidate ...

An internal US Food and Drug Administration (FDA) re-examination of previously submitted data has raised concerns that two generic medications used to treat attention ...

October 7, 2010 — The US Food and Drug Administration (FDA) has approved clonidine hydrochloride, 0.1-mg and 0.2-mg, extended-release tablets (Kapvay; Shionogi Inc ...